NZ600136A - Pyrazine derivatives and their use in the treatment of neurological disorders - Google Patents
Pyrazine derivatives and their use in the treatment of neurological disordersInfo
- Publication number
- NZ600136A NZ600136A NZ60013610A NZ60013610A NZ600136A NZ 600136 A NZ600136 A NZ 600136A NZ 60013610 A NZ60013610 A NZ 60013610A NZ 60013610 A NZ60013610 A NZ 60013610A NZ 600136 A NZ600136 A NZ 600136A
- Authority
- NZ
- New Zealand
- Prior art keywords
- compound
- amino
- treatment
- fluoro
- pyridine
- Prior art date
Links
- 208000012902 Nervous system disease Diseases 0.000 title 1
- 208000025966 Neurological disease Diseases 0.000 title 1
- 150000003216 pyrazines Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 5
- -1 5-cyano-pyridine-2-carbonyl Chemical group 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 239000008186 active pharmaceutical agent Substances 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 229940088679 drug related substance Drugs 0.000 abstract 1
- 208000027061 mild cognitive impairment Diseases 0.000 abstract 1
- FGPUURAPBZPKJF-UHFFFAOYSA-N n-[3-(3-amino-1,5-dimethyl-6-oxo-2h-pyrazin-5-yl)-4-fluorophenyl]-5-bromopyridine-2-carboxamide Chemical compound O=C1N(C)CC(N)=NC1(C)C1=CC(NC(=O)C=2N=CC(Br)=CC=2)=CC=C1F FGPUURAPBZPKJF-UHFFFAOYSA-N 0.000 abstract 1
- FOLBFWMABGBJIK-UHFFFAOYSA-N n-[3-[5-amino-1-(2-methoxyethyl)-3-methyl-6-oxo-2h-pyrazin-3-yl]-4-fluorophenyl]-3,5-dichloropyridine-2-carboxamide Chemical compound N1=C(N)C(=O)N(CCOC)CC1(C)C1=CC(NC(=O)C=2C(=CC(Cl)=CN=2)Cl)=CC=C1F FOLBFWMABGBJIK-UHFFFAOYSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29172409P | 2009-12-31 | 2009-12-31 | |
| PCT/EP2010/070502 WO2011080176A1 (en) | 2009-12-31 | 2010-12-22 | Pyrazine derivatives and their use in the treatment of neurological disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ600136A true NZ600136A (en) | 2013-09-27 |
Family
ID=43598456
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ60013610A NZ600136A (en) | 2009-12-31 | 2010-12-22 | Pyrazine derivatives and their use in the treatment of neurological disorders |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US20120277244A1 (enExample) |
| EP (1) | EP2519515B1 (enExample) |
| JP (1) | JP5600754B2 (enExample) |
| KR (1) | KR101419157B1 (enExample) |
| CN (1) | CN102712621B (enExample) |
| AU (1) | AU2010338365B2 (enExample) |
| BR (1) | BR112012015916A2 (enExample) |
| CA (1) | CA2785341A1 (enExample) |
| CL (1) | CL2012001762A1 (enExample) |
| CR (1) | CR20120332A (enExample) |
| CU (1) | CU20120099A7 (enExample) |
| EA (1) | EA201200952A1 (enExample) |
| EC (1) | ECSP12012065A (enExample) |
| ES (1) | ES2445536T3 (enExample) |
| GT (1) | GT201200219A (enExample) |
| HN (1) | HN2012001413A (enExample) |
| IL (1) | IL220268A0 (enExample) |
| MX (1) | MX2012007754A (enExample) |
| NZ (1) | NZ600136A (enExample) |
| PE (1) | PE20121640A1 (enExample) |
| PH (1) | PH12012501007A1 (enExample) |
| PL (1) | PL2519515T3 (enExample) |
| PT (1) | PT2519515E (enExample) |
| SG (1) | SG181431A1 (enExample) |
| TN (1) | TN2012000249A1 (enExample) |
| WO (1) | WO2011080176A1 (enExample) |
| ZA (1) | ZA201203614B (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006307314C1 (en) | 2005-10-25 | 2011-08-25 | Shionogi & Co., Ltd. | Aminodihydrothiazine derivative |
| ES2476605T3 (es) | 2007-04-24 | 2014-07-15 | Shionogi & Co., Ltd. | Derivados de aminohidrotiazina sustituidos con grupos cíclicos |
| JP5383483B2 (ja) | 2007-04-24 | 2014-01-08 | 塩野義製薬株式会社 | アルツハイマー症治療用医薬組成物 |
| AU2009258496B8 (en) | 2008-06-13 | 2014-06-26 | Shionogi & Co., Ltd. | Sulfur-containing heterocyclic derivative having beta-secretase-inhibiting activity |
| WO2010047372A1 (ja) | 2008-10-22 | 2010-04-29 | 塩野義製薬株式会社 | Ｂａｃｅ１阻害活性を有する２－アミノピリミジン－４－オンおよび２－アミノピリジン誘導体 |
| UA108363C2 (uk) | 2009-10-08 | 2015-04-27 | Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування | |
| UA110467C2 (uk) | 2009-12-11 | 2016-01-12 | Шионогі Енд Ко., Лтд. | Похідні оксазину |
| US20130079349A1 (en) * | 2010-06-09 | 2013-03-28 | Janssen Pharmaceutica Nv | 5-amino-3,6-dihydro-1h-pyrazin-2-one derivatives useful as inhibitors of beta-secretase (bace) |
| PH12012502377A1 (en) | 2010-06-09 | 2014-10-14 | Janssen Pharmaceutica Nv | 5,6-dihydro-2h-[1,4]oxazin-3-yl-amine derivatives useful as inhibitors of beta-secretase (bace) |
| KR20130089231A (ko) * | 2010-06-28 | 2013-08-09 | 얀센 파마슈티카 엔.브이. | 알츠하이머병 및 다른 형태의 치매 치료용으로 유용한 3-아미노-5,6-디하이드로-1ｈ-피라진-2-온 유도체 |
| CN103261199A (zh) | 2010-10-29 | 2013-08-21 | 盐野义制药株式会社 | 萘啶衍生物 |
| JP5766198B2 (ja) | 2010-10-29 | 2015-08-19 | 塩野義製薬株式会社 | 縮合アミノジヒドロピリミジン誘導体 |
| NZ610948A (en) | 2010-12-22 | 2014-06-27 | Janssen Pharmaceutica Nv | 5,6-dihydro-imidazo[1,2-a]pyrazin-8-ylamine derivatives useful as inhibitors of beta-secretase (bace) |
| US8524897B2 (en) | 2011-01-12 | 2013-09-03 | Novartis Ag | Crystalline oxazine derivative |
| PT2663561E (pt) | 2011-01-13 | 2016-06-07 | Novartis Ag | Derivados heterocíclicos novos e sua utilização no tratamento de distúrbios neurológicos |
| JP2014505689A (ja) * | 2011-01-13 | 2014-03-06 | ノバルティス アーゲー | 代謝障害の処置用ｂａｃｅ−２阻害剤 |
| JP5853033B2 (ja) | 2011-03-01 | 2016-02-09 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプＪａｎｓｓｅｎ Ｐｈａｒｍａｃｅｕｔｉｃａ Ｎａａｍｌｏｚｅ Ｖｅｎｎｏｏｔｓｃｈａｐ | β−セクレターゼ（ＢＡＣＥ）の阻害剤として有用な６，７−ジヒドロ−ピラゾロ［１，５−ａ］ピラジン−４−イルアミン誘導体 |
| BR112013022917A2 (pt) | 2011-03-09 | 2016-12-06 | Janssen Pharmaceutica Nv | derivados 3,4-dihidro-pirrolo[1,2-a]pirazino-1-ilamina úteis como inibidores de beta-secretase (bace) |
| EP2694489B1 (en) | 2011-04-07 | 2017-09-06 | Merck Sharp & Dohme Corp. | C5-c6 oxacyclic-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
| US9145426B2 (en) | 2011-04-07 | 2015-09-29 | Merck Sharp & Dohme Corp. | Pyrrolidine-fused thiadiazine dioxide compounds as BACE inhibitors, compositions, and their use |
| AU2012243329B2 (en) | 2011-04-13 | 2015-09-17 | Merck Sharp & Dohme Corp. | 5-substituted iminothiazines and their mono-and dioxides as BACE inhibitors,compositions,and their use |
| CN103608345A (zh) | 2011-04-26 | 2014-02-26 | 盐野义制药株式会社 | 噁嗪衍生物和含有该噁嗪衍生物的bace1抑制剂 |
| KR20140054295A (ko) | 2011-08-22 | 2014-05-08 | 머크 샤프 앤드 돔 코포레이션 | Bace 억제제로서의 2-스피로-치환된 이미노티아진 및 그의 모노- 및 디옥시드, 조성물 및 그의 용도 |
| US8338413B1 (en) | 2012-03-07 | 2012-12-25 | Novartis Ag | Oxazine derivatives and their use in the treatment of neurological disorders |
| EP2912035A4 (en) | 2012-10-24 | 2016-06-15 | Shionogi & Co | DERIVATIVES OF DIHYDROOXAZINE OR OXAZEPINE HAVING BACE1 INHIBITING ACTIVITY |
| AU2013363151A1 (en) | 2012-12-20 | 2015-06-04 | Merck Sharp & Dohme Corp. | C5, C6 oxacyclic-fused iminothiazine dioxide compounds as BACE inhibitors |
| KR102243133B1 (ko) | 2013-06-12 | 2021-04-22 | 얀센 파마슈티카 엔.브이. | 베타-세크레타제(bace) 저해제로서의 4-아미노-6-페닐-6,7-디하이드로[1,2,3]트리아졸로[1,5-a]피라진 유도체 |
| JP6325092B2 (ja) | 2013-06-12 | 2018-05-16 | ヤンセン ファーマシューティカ エヌ．ベー． | βーセクレターゼ（ＢＡＣＥ）の阻害剤としての４−アミノ−６−フェニル−５，６−ジヒドロイミダゾ［１，５−Ａ］ピラジン誘導体 |
| KR102243135B1 (ko) | 2013-06-12 | 2021-04-22 | 얀센 파마슈티카 엔.브이. | 베타-세크레타제(bace) 저해제로서의 4-아미노-6-페닐-5,6-디하이드로이미다조[1,5-a]피라진-3(2h)-온 유도체 |
| EP3233834B1 (en) | 2014-12-18 | 2019-11-13 | Janssen Pharmaceutica NV | 2,3,4,5-tetrahydropyridin-6-amine and 3,4-dihydro-2h-pyrrol-5-amine derivatives useful as inhibitors of beta-secretase |
| CN107011134B (zh) * | 2017-04-28 | 2021-02-05 | 浙江中欣氟材股份有限公司 | 一种2-氟-5-溴苯乙酮的合成方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL6911868A (enExample) | 1968-08-31 | 1970-03-03 | ||
| AUPQ319899A0 (en) * | 1999-10-01 | 1999-10-28 | Fujisawa Pharmaceutical Co., Ltd. | Amide compounds |
| WO2002060492A1 (en) * | 2001-01-30 | 2002-08-08 | Cytopia Pty Ltd | Methods of inhibiting kinases |
| JP2007524596A (ja) | 2003-02-28 | 2007-08-30 | トランスフォーム・ファーマシューティカルズ・インコーポレイテッド | 共結晶医薬組成物 |
| EP1702919B1 (en) | 2003-12-29 | 2012-05-30 | Msd K.K. | Novel 2-heteroaryl-substituted benzimidazole derivative |
| US20050215884A1 (en) * | 2004-02-27 | 2005-09-29 | Greicius Michael D | Evaluation of Alzheimer's disease using an independent component analysis of an individual's resting-state functional MRI |
| AU2006307314C1 (en) * | 2005-10-25 | 2011-08-25 | Shionogi & Co., Ltd. | Aminodihydrothiazine derivative |
| SI1945632T1 (sl) * | 2005-11-08 | 2014-03-31 | Vertex Pharmaceuticals Incorporated | Heterocikliäśni modulatorji za prenaĺ alce z atp-vezavno kaseto |
| EA200900799A1 (ru) * | 2006-12-22 | 2009-12-30 | Новартис Аг | Гетероарилгетероарильные соединения как ингибиторы cdk, предназначенные для лечения рака, воспаления и борьбы с вирусными инфекциями |
| ES2548774T3 (es) | 2008-01-18 | 2015-10-20 | Eisai R&D Management Co., Ltd. | Derivado de aminodihidrotiazina condensado |
| WO2010047372A1 (ja) | 2008-10-22 | 2010-04-29 | 塩野義製薬株式会社 | Ｂａｃｅ１阻害活性を有する２－アミノピリミジン－４－オンおよび２－アミノピリジン誘導体 |
| UY32799A (es) * | 2009-07-24 | 2011-02-28 | Novartis Ag | Derivados de oxazina y su uso en el tratamiento de trastornos neurológicos |
| US20130079349A1 (en) * | 2010-06-09 | 2013-03-28 | Janssen Pharmaceutica Nv | 5-amino-3,6-dihydro-1h-pyrazin-2-one derivatives useful as inhibitors of beta-secretase (bace) |
| KR20130089231A (ko) * | 2010-06-28 | 2013-08-09 | 얀센 파마슈티카 엔.브이. | 알츠하이머병 및 다른 형태의 치매 치료용으로 유용한 3-아미노-5,6-디하이드로-1ｈ-피라진-2-온 유도체 |
-
2010
- 2010-12-22 US US13/518,907 patent/US20120277244A1/en not_active Abandoned
- 2010-12-22 JP JP2012546418A patent/JP5600754B2/ja not_active Expired - Fee Related
- 2010-12-22 EP EP20100796064 patent/EP2519515B1/en active Active
- 2010-12-22 KR KR1020127019872A patent/KR101419157B1/ko not_active Expired - Fee Related
- 2010-12-22 PE PE2012000897A patent/PE20121640A1/es not_active Application Discontinuation
- 2010-12-22 CN CN201080060047.7A patent/CN102712621B/zh not_active Expired - Fee Related
- 2010-12-22 BR BR112012015916A patent/BR112012015916A2/pt not_active IP Right Cessation
- 2010-12-22 AU AU2010338365A patent/AU2010338365B2/en not_active Ceased
- 2010-12-22 SG SG2012036935A patent/SG181431A1/en unknown
- 2010-12-22 NZ NZ60013610A patent/NZ600136A/xx not_active IP Right Cessation
- 2010-12-22 PH PH1/2012/501007A patent/PH12012501007A1/en unknown
- 2010-12-22 PT PT10796064T patent/PT2519515E/pt unknown
- 2010-12-22 PL PL10796064T patent/PL2519515T3/pl unknown
- 2010-12-22 CA CA 2785341 patent/CA2785341A1/en not_active Abandoned
- 2010-12-22 WO PCT/EP2010/070502 patent/WO2011080176A1/en not_active Ceased
- 2010-12-22 MX MX2012007754A patent/MX2012007754A/es active IP Right Grant
- 2010-12-22 EA EA201200952A patent/EA201200952A1/ru unknown
- 2010-12-22 ES ES10796064T patent/ES2445536T3/es active Active
-
2012
- 2012-05-17 ZA ZA2012/03614A patent/ZA201203614B/en unknown
- 2012-05-22 TN TNP2012000249A patent/TN2012000249A1/en unknown
- 2012-06-07 IL IL220268A patent/IL220268A0/en unknown
- 2012-06-19 CR CR20120332A patent/CR20120332A/es unknown
- 2012-06-25 CU CU20120099A patent/CU20120099A7/es unknown
- 2012-06-27 CL CL2012001762A patent/CL2012001762A1/es unknown
- 2012-06-28 HN HN2012001413A patent/HN2012001413A/es unknown
- 2012-06-28 GT GT201200219A patent/GT201200219A/es unknown
- 2012-07-25 EC ECSP12012065 patent/ECSP12012065A/es unknown
-
2015
- 2015-07-21 US US14/805,446 patent/US20150322038A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ600136A (en) | Pyrazine derivatives and their use in the treatment of neurological disorders | |
| NZ592961A (en) | Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators | |
| NZ597107A (en) | Heterocyclic compounds for the treatment of neurological and psychological disorders | |
| NO20084853L (no) | Forbindelser som er agonister av muscarinreseptorer og som kan vaere effektive i behandling av smerte, Alzheimers sykdom og/eller schizofreni | |
| WO2006119504A3 (en) | Fused heterocyclic compounds, and compositions and uses thereof | |
| NZ596579A (en) | Bace inhibitors | |
| MX2012006493A (es) | Derivados de 2-amino-5,5-difluor-5, 6-dihidro-4h-[1,3]oxazin-4-il) -fenil]-amida como inhibidores de la bace1 y/o bace2. | |
| WO2009050242A3 (de) | Heterocyclus-substituierte piperazino-dihydrothienopyrimidine | |
| NZ604004A (en) | Pyridone and aza-pyridone compounds and methods of use | |
| NZ597529A (en) | Oxazine derivatives and their use as bace inhibitors for the treatment of neurological disorders | |
| NZ600674A (en) | Quinoline amide m1 receptor positive allosteric modulators | |
| EA019970B8 (ru) | Производные имидазолидиндиона | |
| WO2008002621A3 (en) | Benzyl-substituted quinolone m1 receptor positive allosteric modulators | |
| TN2009000471A1 (fr) | Composes amino-heterocycliques | |
| MY155836A (en) | Thienopyridone derivatives as amp-activated protein kinase (ampk) activators | |
| HRP20141116T1 (hr) | 1h-kinazolin-2,4-dioni | |
| PT2139334E (pt) | Compostos heterocíclicos fusionados de 2-cianofenilo, e composições e utilizações dos mesmos | |
| UA112055C2 (uk) | Солі 4-[2-[[5-метил-1-(2-нафталініл)-1h-піразол-3-іл]оксі]етил]морфоліну | |
| WO2007017135A3 (en) | Process for the preparation of olmesartan medoxomil | |
| NZ601684A (en) | Salt of fused heterocyclic derivative and crystal thereof | |
| MX2012002583A (es) | Moduladores de piranil aril metil benzoquinazolinona alostericos positivos del receptor m1. | |
| ATE357453T1 (de) | Comt-inhibitoren | |
| NZ594369A (en) | Combination of HMG-CoA reductase inhibitors with phosphodiesterase 4 inhibitors for the treatment of inflammatory pulmonary diseases | |
| NZ584998A (en) | Cycloalkyloxy-and heterocycloalkyloxypyridine compounds as modulators of the histamine h3 receptor | |
| DE602005027677D1 (de) | 1,3,4-oxadiazol-2-one als ppar-delta-modulatoren und deren verwendung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| ERR | Error or correction |
Free format text: THE OWNER HAS BEEN CORRECTED TO 890887, NOVARTIS AG, LICHTSTRASSE 35, CH-4056 BASEL, CH Effective date: 20140409 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 22 DEC 2017 BY CPA GLOBAL Effective date: 20140911 |
|
| LAPS | Patent lapsed |